Published September 8, 2017 | Version v1
Conference paper

Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)

Contributors

Others:

Description

International audience

Abstract

IF 11.855

Additional details

Identifiers

URL
https://hal.science/hal-01626269
URN
urn:oai:HAL:hal-01626269v1

Origin repository

Origin repository
UNICA